Let's talk about your next study New study? Request a quote →
Loading...
PBMC Processing Services

PBMC Processing Services

Density gradient isolation from whole blood, buffy coats, and leukapheresis collections, viable counting, phenotyping, and cryopreservation, processed on receipt

Cryopreserved peripheral blood mononuclear cells (PBMCs) carry the handling of the blood before freezing into every measurement made on them. A longer interval between venipuncture and cryopreservation has been associated with lower cell recovery, co-purification of activated granulocytes with the mononuclear fraction, and weaker antigen-specific T-cell responses, so two samples, or two collection sites, can differ for reasons unrelated to the biology a study is measuring. Central processing addresses this by putting every sample through one procedure in one laboratory, processed on receipt, and by attaching a processing record to each one: the intervals from collection to processing and to freezing, a viable count, and a phenotype that includes the granulocyte fraction. If your program needs PBMCs that were handled the same way at every visit, with the record to show it, central processing answers that question.

How We Process PBMCs From Whole Blood and Leukapheresis

PBMC processing turns a blood or leukapheresis collection into mononuclear cells, counted, characterized, and frozen, through a fixed sequence of steps that we run under standard operating procedures.

Intake

Transfer

Density gradient separation

Harvest and washes

Viable count

Phenotype

Cell subset isolation

Cryopreservation or snap-freezing

What you receive

01

Intake

Each sample is checked against its manifest, and the collection time supplied with it is recorded alongside the time processing starts and the time the cells enter the freezing container. Clotting and hemolysis are documented. Blood is held at room temperature from receipt and never refrigerated, because cold storage of whole blood has been associated with a marked increase in granulocyte contamination of the PBMC fraction.

02

Transfer

Leukapheresis collections are drawn off through the bag’s sterile port with a sterile transfer set. This keeps the transfer sterile, and it means a bag that may carry a bloodborne pathogen is never cut open and poured.

03

Density gradient separation

PBMCs are separated by density gradient centrifugation over Lymphoprep or Ficoll-Paque PLUS, both 1.077 g/mL media, as the client prefers. Separation runs by manual overlay or in SepMate tubes, a choice we make with you at scoping.

04

Harvest and washes

With manual overlay, the mononuclear band is collected with as little gradient medium and plasma as possible to minimize granulocyte and platelet carryover. With SepMate tubes, the layer above the insert is poured off. Either way, the cells are then washed twice to remove residual medium and plasma.

05

Viable count

Cells are counted with acridine orange and propidium iodide on a Revvity Cellometer Ascend. Both dyes stain nucleic acid, so only nucleated cells are counted and residual red cells and platelets do not inflate the result, and an automated count removes the judgment calls that make manual counts differ between technicians. Yield per milliliter of blood is recorded for every sample.

06

Phenotype

For routine collections from human donors, a portion of the fresh PBMCs is stained with a viability dye and a standard panel against CD45, CD3, CD4, CD8, CD14, CD15, CD19, and CD56, which reports viable leukocytes, T cells, CD4+ and CD8+ T cells, B cells, NK cells, monocytes, and CD15+ granulocytes as fractions of the preparation. The standard panel is a starting point that can be customized to your study’s needs, and panels for non-human primate (NHP) samples are available and can be customized in the same way.

07

Cell subset isolation

Where a study needs defined populations rather than bulk PBMCs, cells can be isolated from the fresh preparation by immunomagnetic selection before freezing, and each population cryopreserved on its own. See Cell Subset Isolation.

08

Cryopreservation or snap-freezing

For viable cryopreservation, cells are resuspended in chilled freezing medium and aliquoted at the concentration and volume the protocol sets. We use CryoStor CS10, which is free of animal products, and freeze in 90% heat-inactivated fetal bovine serum with 10% DMSO, or another medium, when a client prefers it. After a brief, timed equilibration in the chilled medium to allow the cryoprotectant to penetrate and the cells to adjust osmotically before cooling begins, the vials undergo controlled-rate cooling in an alcohol-free freezing container in a -80°C freezer and then move to vapor-phase liquid nitrogen. When you want cell pellets rather than viable cells, the cells are snap-frozen instead.

09

What you receive

Each sample is returned as viably cryopreserved vials, snap-frozen pellets, or both, with plasma from the same draw where it was requested, and a processing record: viable cell count and viability, yield per milliliter, phenotype composition, cells per vial and the number of vials, the intervals from collection to processing and to freezing, and any deviation noted at intake.

Why the Hours Before Processing Matter

The hours between venipuncture and processing are the part of the workflow that no laboratory controls directly, and they leave a mark on the cells. In blood held at room temperature, granulocytes become activated and more of them co-purify with the mononuclear fraction as the delay lengthens, and refrigerating the blood has been reported to make this markedly worse. That contamination has been associated with suppressed T-cell function in the resulting preparation. In samples from HIV vaccine trials, the interval from venipuncture to cryopreservation was the processing parameter most strongly associated with T-cell assay performance, with recovery and IFN-γ ELISpot frequencies lower when processing was delayed by a day. Procedures shared across clinical trial networks accordingly call for blood to be processed and frozen promptly after the draw.

Processing on receipt shortens the part of that interval that falls to us, and the processing record shows the rest. The granulocyte fraction is the reason the phenotype is part of processing: measuring it puts a pre-analytical problem into the record, where it can be accounted for, rather than leaving it to surface later as a weak or variable assay. Read together with the recorded intervals, it lets a study see, sample by sample, which collections were affected by time in transit.

Blood should travel at room temperature, never refrigerated or on ice, and reach us by the fastest route the site has.

CollectionProcessingFreezingCollection to processingCollection to freezing
Blood can reach uswithin the time yourendpoints tolerateCentralprocessingA site too far away,or a processingvendorProcess locallyand qualify

Central Processing or Processing at the Site

Where blood can reach us within the time your endpoints tolerate, we recommend sending it to us. Every sample then goes through one separation procedure, one counting method, and one phenotyping panel, which removes the processing site as a source of variance and leaves a single, comparable record across the study.

Where a site is too far away for that, or a study already relies on a processing vendor, the alternative is to process locally and qualify the people and laboratories doing it. Our PBMC processing qualification service thaws vials each site prepares and measures post-thaw viability, recovery, and phenotype, with an optional sterility check, against criteria agreed before the first participant sample. Many multi-site studies use both, with central processing for the sites within reach and qualification for the rest.

As an illustration, consider a multi-site vaccine study. The sites within shipping range send whole blood to us at room temperature, and each draw is processed on receipt under one procedure, so every sample carries the same kind of processing record. Plasma is saved from each draw for soluble markers, and the PBMCs are frozen in aliquots sized for the ELISpot and ICS readouts planned at each timepoint, then banked so that all of a participant’s timepoints can be thawed and tested in one run. A site too distant to ship in time processes its own samples after its operators are qualified, and its vials are assessed at intervals through the study, so its data can be read alongside the centrally processed samples.

Sample Types, Species, and What You Receive

Central processing serves any study that draws blood or collects leukapheresis for immune or molecular endpoints, from preclinical NHP studies through clinical trials.

Sample types

Anticoagulated whole blood in collection tubes or bags, buffy coats, and leukapheresis collections. The anticoagulant is agreed at scoping, and large or multi-tube collections are scoped to the protocol.

Species

Human and NHP samples, most often from rhesus and cynomolgus macaques, and samples from other common animal model species. Phenotyping is matched to the species at scoping. See NHP Study Bioanalysis.

Outputs

Viably cryopreserved PBMCs, snap-frozen pellets, or both, and plasma from the same draw on request.

Freezing medium

CryoStor CS10 or 90% fetal bovine serum with 10% DMSO, or another medium if you prefer.

Storage

Vapor-phase liquid nitrogen onsite, with the cold chain maintained on every transfer. Vials are not returned from liquid nitrogen to a -80°C freezer unless you direct it.

Shipment of frozen cells

On dry ice or in a liquid nitrogen dry shipper. We recommend the dry shipper, which keeps cells colder than dry ice in transit and leaves more margin if a shipment is delayed, and shipment in liquid nitrogen has been associated with better post-thaw viability and recovery.

Biosafety

All samples are processed in our BSL-2+ laboratory, which adds enhanced biosafety practices to BSL-2 containment for work with bloodborne pathogens and viral vectors. See Infectious Sample Processing.

Workflow

Steps

0 07

Consultation.

Our scientists review the sample type and volume per draw, the species, the collection sites and shipping routes, the number of participants and timepoints, and the assays the cells will support.

Processing specification.

We agree the outputs (viable vials, pellets, plasma), the freezing medium, the cells per vial and the aliquot plan, the vial labels, and the shipping instructions for each site. Labels carry the sample identifier, the processing date, and the cell count by default, with any further fields your protocol requires.

Collection and shipment.

Sites ship blood at room temperature with a manifest and the collection time for each sample.

Receipt and processing.

Samples are processed on receipt: density gradient separation, washes, viable count, and phenotype.

Freezing and storage.

Cells are cryopreserved or snap-frozen and moved to vapor-phase liquid nitrogen.

Reporting.

The processing record for each sample is reported, with any deviation noted.

Downstream handling.

Cells stay in the bank, move into the assays scoped with us, or ship to your laboratory.

Where Processing Stops

What processing shows

Processing prepares and characterizes cells, and its record shows how each sample was handled.

It does not show how the cells will perform after thaw or what they will do in an assay, and it cannot undo what happened before they arrived. Each of those has its own answer.

01

Post-thaw performance.

A count and viability at processing describe the cells before freezing. Post-thaw viability and recovery are measured when the cells are thawed, and our PBMC processing qualification service offers that measurement on its own.

02

Function.

The phenotype reports lineage composition, not antigen-specific function. ELISpot and FluoroSpot, intracellular cytokine staining, and T-cell proliferation report function.

03

What happened before the sample arrived.

Processing cannot reverse a long transit, cold exposure, or an anticoagulant the protocol did not call for. The processing record makes those conditions visible, so a study can account for them.

04

Granulocyte biology.

Density gradient separation removes most granulocytes by design, so a study of granulocytes needs whole blood or a granulocyte isolation instead.

Talk to our scientists about your study.

Our Laboratory and Scientific Team

We use cryopreserved PBMCs in our own functional assays, where the quality of the cells sets the quality of the data, and that shapes how we process them. We process to maximize yield and to preserve the integrity and function of the cells through freezing and thaw, and we plan aliquoting strategies with you that get the most from each sample.

 

Processing, phenotyping, and downstream assays run under standard operating procedures in our CAP-accredited, CLIA-certified laboratory in Baltimore, Maryland. Accelevir is scientist run, with technical specialists and lead scientists working as one team from protocol design to final report, so a study design can adapt as the biology evolves.

Our Laboratory and Scientific Team

01

The processing record and the assay data in one laboratory.

Processing at one laboratory and testing at another can separate a sample’s handling history from the data it produced. When the downstream assays run here, the intervals, counts, and phenotype for each sample sit alongside its results.

02

Central processing and site qualification on one standard.

Differences in how sites process PBMCs can enter a dataset as variance that no assay removes. Central processing puts every sample through the same separation, count, and phenotype, and qualification holds the sites that process their own to the same measurements.

03

Preclinical to clinical in one laboratory.

Moving a method from a preclinical vendor to a clinical laboratory can mean requalifying it mid-program. We partner with the vivarium of your choice for NHP studies, then carry the work into clinical trials in the same laboratory.

Talk to our scientists about your study.

Set the Processing Specification Before the First Draw

The right processing specification depends on what you bring: the sample type, species, and volume per draw; whether you want viable cells, pellets, plasma, or all three; where your collection sites are and how blood will reach us; the number of participants and timepoints; the assays the cells will support, here or elsewhere, and the input each needs; any freezing medium, vial, or labeling requirement your protocol sets; and the question your next milestone depends on. Share those with our scientists, and we will return a processing specification, an aliquot plan, and an itemized proposal matched to your study design.

FAQ

Frequently Asked Questions

What sample types and species do you process?

Whole blood in collection tubes or bags, buffy coats, and leukapheresis collections. We process human and NHP samples, most often from rhesus and cynomolgus macaques, and samples from other common animal model species. The anticoagulant is agreed at scoping, and all samples are processed in our BSL-2+ laboratory.

How should blood be shipped to you?

At room temperature, never refrigerated or on ice, with a manifest that includes the collection time for each sample, by the fastest route the site has. We provide shipping instructions for each site as part of the processing specification.

How quickly do you process samples?

Samples are processed on receipt, with rapid-turnaround processing. The time in transit sits outside the laboratory, so we do not promise a fixed window from venipuncture, but the processing record shows the interval for every sample.

Should we choose manual overlay or SepMate tubes?

We make that choice with you at scoping. SepMate tubes are faster, with a slightly lower yield than manual overlay, so they suit a study processing many draws of roughly 20 mL or less, or a client who prefers them. Manual overlay recovers more cells, so it suits a study that needs large cell numbers from each draw. The gradient medium, Lymphoprep or Ficoll-Paque PLUS, is your choice either way.

What viability and yield should we expect?

Both depend on the time from draw to processing, the temperature in transit, the anticoagulant, the donor, and technique, so we prefer to discuss figures in the context of a study design. Viability and yield are measured and reported for every sample.

Which freezing medium should we choose?

We use CryoStor CS10, which is free of animal products, and freeze in 90% fetal bovine serum with 10% DMSO, or another medium, when a client prefers it, for example to match samples already banked in that medium. Each is cooled at a controlled rate after the same chilled equilibration.

Can you save plasma or make cell pellets from the same draw?

Yes. Plasma can be saved from each draw for viral load or soluble markers, and cells can be snap-frozen as pellets when you want them, alongside or instead of viable vials.

How are frozen cells shipped?

On dry ice or in a liquid nitrogen dry shipper. We recommend the dry shipper, which keeps the cells colder in transit and leaves more margin if a shipment is delayed.

Some of our sites process their own samples. Can you check their work?
Yes. PBMC processing qualification thaws vials each site prepares and measures post-thaw viability, recovery, and phenotype, with an optional sterility check, against criteria agreed in advance.
What is in the processing record?

For each sample: the viable cell count and viability, yield per milliliter, the phenotype, cells per vial and the number of vials or pellets, plasma aliquots where saved, the intervals from collection to processing and to freezing, and any deviation noted at intake.

Accelevir Diagnostics, LLC is a CAP-accredited, CLIA-certified laboratory. Services are provided for research use in support of clinical and preclinical studies and are not intended for diagnostic, therapeutic, prognostic, or patient-management use.